Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CRDF

CRDF - Cardiff Oncology, Inc. Stock Price, Fair Value and News

$1.62-0.38 (-19.00%)
Market Closed

11/100

CRDF

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

11/100

CRDF

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.32

Target 3M

$2.61

Target 6M

$2.46

CRDF Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CRDF Price Action

Last 7 days

-43.9%

Last 30 days

-45.1%

Last 90 days

-27.3%

Trailing 12 Months

-52.6%

CRDF RSI Chart

CRDF Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CRDF Valuation

Market Cap

109.1M

Price/Earnings (Trailing)

-2.16

Price/Sales (Trailing)

218.03

Price/Free Cashflow

-3.61

CRDF Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.32

Target 3M

$2.61

Target 6M

$2.46

CRDF Fundamentals

CRDF Revenue

Revenue (TTM)

500.5K

Rev. Growth (Yr)

-27.27%

Rev. Growth (Qtr)

-0.83%

CRDF Earnings

Earnings (TTM)

-50.4M

Earnings Growth (Yr)

5.04%

Earnings Growth (Qtr)

19.26%

CRDF Profitability

Operating Margin

100.00%

Return on Equity

-103.34%

Return on Assets

-79.06%

Free Cashflow Yield

-27.67%

CRDF Investor Care

Shares Dilution (1Y)

31.73%

Diluted EPS (TTM)

-0.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025587.5K545.5K500.5K0
2024610.0K665.0K689.0K683.5K
2023625.8K865.5K1.1M1.3M
2022438.5K620.5K1.0M386.0K
2021355.0K383.0K317.0K365.5K
2020266.3K239.6K323.9K366.0K
2019340.2K298.2K261.5K260.3K
2018510.5K520.3K485.3K378.3K
2017356.0K354.0K388.4K505.4K
2016306.0K361.0K392.0K381.0K
2015296.0K289.0K290.0K313.0K
2014251.0K258.0K271.0K280.0K
2013536.0K543.0K375.0K259.0K
2012202.6K164.8K321.8K451.0K
2011000257.7K
Get all data in R, Python etc through our Historical Stock Data APIs

About Cardiff Oncology, Inc.

CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. It primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
 CEO
 WEBSITEcardiffoncology.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES25

Cardiff Oncology, Inc. Frequently Asked Questions

CRDF is the stock ticker symbol of Cardiff Oncology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Cardiff Oncology, Inc. is 109.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CRDF's fair value in chart for subscribers.

The fair value guage provides a quick view whether CRDF is over valued or under valued. Whether Cardiff Oncology, Inc. is cheap or expensive depends on the assumptions which impact Cardiff Oncology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRDF.

As of Wed Jan 28 2026, CRDF's PE ratio (Price to Earnings) is -2.16 and Price to Sales (PS) ratio is 218.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRDF PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Cardiff Oncology, Inc. has provided -0.399 (multiply by 100 for percentage) rate of return.